Current Report Filing (8-k)
2016年10月27日 - 7:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
October 26, 2016
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37428
|
|
26-3474527
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
1880
Century Park East, Suite 1000
Los
Angeles, California
|
|
90067
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry into a Material Definitive Agreement.
On
October 26, 2016, Ritter Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting
Agreement”) with Aegis Capital Corp., as representative of the several underwriters named therein (collectively, the “Underwriters”),
relating to the public offering (the “Offering”) of 2,127,660 shares of the Company’s common stock, $0.001 par
value per share (the “Common Stock”), at a public offering price of $2.35 per share for total gross proceeds of $5,000,000,
or $4,650,000 after deducting underwriting discounts and commissions. In addition, the Underwriters were granted an over-allotment
option exercisable for 30 days after the Offering for 212,766 shares of Common Stock at a public offering price of $2.35 per share.
The Company expects to receive approximately $5,115,000 in gross proceeds if the Underwriters’ over-allotment option is
exercised in full. The Company currently intends to use the estimated net proceeds from the Offering for operations and other
general corporate purposes.
The
Offering is expected to close on or about October 31, 2016, subject to the satisfaction of customary closing conditions. The Underwriting
Agreement contains customary representations and warranties, conditions to closing, indemnification obligations of the Company
and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties,
and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related “lock-up”
agreements, the Company and each director and executive officer of the Company has agreed, subject to exceptions, not to sell,
transfer or otherwise dispose of securities of the Company for a period of time specified in the Underwriting Agreement.
The
foregoing descriptions of the Underwriting Agreement are not complete and are qualified in their entirety by reference to the
full text of the Underwriting Agreement, which is filed as Exhibit 1.1, to this report and is incorporated by reference herein.
The
shares are being offered and sold pursuant to a prospectus, dated August 23, 2016, and a preliminary prospectus supplement, dated
October 26, 2016, in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-213087),
declared effective by the United States Securities and Exchange Commission on August 23, 2016.
A
copy of the opinion of Reed Smith LLP relating to the legality of the issuance and sale of the shares of Common Stock in the Offering
is attached as Exhibit 5.1 hereto.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
1.1
|
|
Underwriting
Agreement, dated October 26, 2016, between Ritter Pharmaceuticals, Inc. and Aegis Capital Corp.
|
|
|
|
5.1
|
|
Opinion
of Reed Smith LLP
|
|
|
|
23.1
|
|
Consent
of Reed Smith LLP (included in Exhibit 5.1)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
RITTER
PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/
Michael D. Step
|
|
Name:
|
Michael
D. Step
|
|
Title:
|
Chief
Executive Officer
|
Date:
October 26, 2016
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Ritter Pharmaceuticals Inc (ナスダック市場): 0 recent articles
その他のRitter Pharmaceuticals Incニュース記事